CSTL RSI Chart
Last 7 days
0.1%
Last 30 days
28.8%
Last 90 days
-4.1%
Trailing 12 Months
3.2%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 250.7M | 0 | 0 | 0 |
2023 | 152.2M | 167.5M | 192.0M | 219.8M |
2022 | 98.1M | 110.2M | 123.7M | 137.0M |
2021 | 68.0M | 78.1M | 86.3M | 94.1M |
2020 | 60.6M | 62.5M | 63.0M | 62.6M |
2019 | 27.8M | 34.6M | 45.7M | 51.9M |
2018 | 0 | 0 | 0 | 22.8M |
Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index
Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>
Returns of $10,000 invested in:
Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224
Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
May 06, 2024 | maetzold derek j | sold | -9,541 | 24.72 | -386 | pres. & chief exec. officer |
May 06, 2024 | maetzold derek j | sold | -29,960 | 24.72 | -1,212 | pres. & chief exec. officer |
May 06, 2024 | bradbury daniel | sold | -182,164 | 24.64 | -7,393 | - |
May 06, 2024 | bradbury daniel | sold | -196,307 | 24.64 | -7,967 | - |
May 06, 2024 | maetzold derek j | sold | -58,537 | 24.72 | -2,368 | pres. & chief exec. officer |
May 06, 2024 | bradbury daniel | sold | -196,208 | 24.64 | -7,963 | - |
Which funds bought or sold CSTL recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 16, 2024 | JANE STREET GROUP, LLC | sold off | -100 | -935,515 | - | -% |
May 16, 2024 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | reduced | -4.79 | -13,139 | 564,471 | -% |
May 15, 2024 | Bellevue Group AG | reduced | -1.00 | 430,166 | 27,024,900 | 0.41% |
May 15, 2024 | Invenomic Capital Management LP | reduced | -2.97 | -14,988 | 3,692,720 | 0.20% |
May 15, 2024 | Royal Bank of Canada | reduced | -67.96 | -142,000 | 70,000 | -% |
May 15, 2024 | JANUS HENDERSON GROUP PLC | reduced | -0.04 | 4,875 | 205,013 | -% |
May 15, 2024 | Alpha DNA Investment Management LLC | new | - | 510,335 | 510,335 | 0.19% |
May 15, 2024 | UBS ASSET MANAGEMENT AMERICAS LLC | added | 16.61 | 115,812 | 704,105 | -% |
May 15, 2024 | SHERBROOKE PARK ADVISERS LLC | new | - | 461,274 | 461,274 | 0.09% |
May 15, 2024 | PRICE T ROWE ASSOCIATES INC /MD/ | added | 6.69 | 35,000 | 400,000 | -% |
Unveiling Castle Biosciences Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Castle Biosciences Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
DHR | 196.9B | 23.7B | 44.73 | 8.29 | ||||
A | 45.2B | 6.7B | 36.57 | 6.71 | ||||
IDXX | 44.9B | 3.7B | 51.83 | 12.06 | ||||
DGX | 16.0B | 9.3B | 18.95 | 1.73 | ||||
NTRA | 13.1B | 1.2B | -35.76 | 10.81 | ||||
MEDP | 12.2B | 2.0B | 38.94 | 6.2 | ||||
CRL | 11.4B | 4.1B | 26.02 | 2.78 | ||||
EXAS | 9.3B | 2.5B | -38.69 | 3.67 | ||||
MID-CAP | ||||||||
GH | 3.1B | 603.7M | -6.73 | 5.14 | ||||
NEOG | 2.9B | 929.2M | 1.9K | 3.16 | ||||
SMALL-CAP | ||||||||
CDNA | 808.3M | 275.1M | -4.41 | 2.94 | ||||
ACRS | 84.8M | 31.1M | -1.1 | 2.73 | ||||
AWH | 33.0M | 9.2M | -2.24 | 3.6 | ||||
APDN | 2.5M | 5.5M | -0.2 | 0.45 | ||||
BIOC | 183.8K | 25.9M | -0.01 | 0.01 |
Castle Biosciences Inc News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Revenue | 10.4% | 73.00 | 66.00 | 61.00 | 50.00 | 42.00 | 38.00 | 37.00 | 35.00 | 27.00 | 25.00 | 23.00 | 23.00 | 23.00 | 17.00 | 15.00 | 13.00 | 17.00 | 18.00 | 15.00 | 11.00 | 9.00 |
Cost Of Revenue | 11.8% | 14.00 | 12.00 | 11.00 | 11.00 | 10.00 | 10.00 | 9.00 | 8.00 | 6.00 | 5.00 | 5.00 | 4.00 | 3.00 | - | 2.00 | 2.00 | - | - | - | - | - |
Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | 20.00 | 15.00 | 13.00 | 11.00 | 15.00 | 16.00 | 13.00 | 9.00 | 7.00 |
Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | 24.00 | - | - | - | 14.00 | 13.00 | 9.00 | 8.00 | 7.00 |
S&GA Expenses | 10.0% | 48.00 | 44.00 | 45.00 | 45.00 | 47.00 | 38.00 | 37.00 | 37.00 | 30.00 | 25.00 | 23.00 | 21.00 | 18.00 | 15.00 | 12.00 | 10.00 | 11.00 | 10.00 | 7.00 | 7.00 | 6.00 |
R&D Expenses | 6.3% | 14.00 | 13.00 | 13.00 | 13.00 | 14.00 | 11.00 | 11.00 | 12.00 | 11.00 | 9.00 | 8.00 | 7.00 | 6.00 | 5.00 | 3.00 | 3.00 | 3.00 | 3.00 | 2.00 | 1.00 | 1.00 |
Interest Expenses | 600.0% | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | - | - | 0.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 2.00 | 1.00 |
Income Taxes | 15.4% | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | -1.96 | 0.00 | -1.77 | - | 0.00 | - | 0.00 | - | - | - | 0.00 | - | - | - |
Net Income | 1.8% | -2.53 | -2.58 | -6.90 | -18.78 | -29.20 | -20.62 | -20.25 | -1.65 | -24.62 | -6.43 | -11.79 | -8.79 | -4.28 | -4.89 | -4.59 | -1.38 | 1.00 | 2.00 | 6.00 | -1.27 | -1.36 |
Net Income Margin | 53.0% | -0.12* | -0.26* | -0.39* | -0.53* | -0.47* | -0.49* | -0.43* | -0.40* | -0.53* | -0.33* | -0.34* | -0.29* | - | - | - | - | - | - | - | - | - |
Free Cashflow | -208.1% | -15.99 | 15.00 | 3.00 | -7.82 | -28.78 | -7.79 | -7.26 | -10.41 | -21.83 | -3.67 | -7.06 | -7.35 | - | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2018Q4 |
Assets | 1.1% | 459 | 453 | 436 | 425 | 427 | 447 | 458 | 458 | 444 | 463 | 434 | 436 | 437 | 439 | 210 | 202 | 120 | 120 | 113 | 33.00 | 22.00 |
Current Assets | 0.0% | 296 | 296 | 280 | 269 | 271 | 292 | 299 | 305 | 336 | 354 | 390 | 392 | 427 | 430 | 201 | 196 | 117 | 117 | 110 | 29.00 | 18.00 |
Cash Equivalents | -16.0% | 83.00 | 99.00 | 91.00 | 96.00 | 115 | 123 | 134 | 273 | 309 | 330 | 363 | 368 | 407 | 410 | 183 | 180 | 99.00 | 99.00 | 94.00 | 17.00 | 4.00 |
Inventory | -3.7% | 8.00 | 8.00 | 6.00 | 6.00 | 5.00 | 4.00 | 4.00 | 3.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
Net PPE | - | - | - | 22.00 | 21.00 | 18.00 | 14.00 | 13.00 | 11.00 | 9.00 | 10.00 | 9.00 | 8.00 | 8.00 | 7.00 | 7.00 | 5.00 | 3.00 | 2.00 | 2.00 | 2.00 | 2.00 |
Liabilities | -9.7% | 56.00 | 62.00 | 50.00 | 47.00 | 42.00 | 48.00 | 46.00 | 37.00 | 47.00 | 51.00 | 22.00 | 20.00 | 19.00 | 24.00 | 44.00 | 44.00 | 32.00 | 35.00 | 31.00 | 37.00 | 32.00 |
Current Liabilities | -33.0% | 32.00 | 48.00 | 36.00 | 34.00 | 30.00 | 36.00 | 32.00 | 28.00 | 40.00 | 25.00 | 21.00 | 19.00 | 18.00 | 21.00 | 30.00 | 28.00 | 15.00 | 15.00 | 9.00 | 12.00 | 7.00 |
Short Term Borrowings | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 4.00 | - |
Long Term Debt | - | 10.00 | - | - | - | - | - | - | - | - | - | - | - | - | - | 12.00 | 15.00 | 17.00 | 19.00 | 22.00 | 24.00 | 25.00 |
LT Debt, Current | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 10.00 | 10.00 | 8.00 | 6.00 | 3.00 | 1.00 | - |
LT Debt, Non Current | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 12.00 | 15.00 | 17.00 | 19.00 | 22.00 | 24.00 | 25.00 |
Shareholder's Equity | 2.9% | 402 | 391 | 386 | 379 | 385 | 399 | 411 | 422 | 397 | 412 | 412 | 416 | 419 | 416 | 167 | 158 | 88.00 | 85.00 | 82.00 | - | - |
Retained Earnings | -1.2% | -220 | -218 | -215 | -208 | -190 | -160 | -140 | -120 | -118 | -93.77 | -87.36 | -75.57 | -66.78 | -62.50 | -57.61 | -53.02 | -51.64 | -52.21 | -54.30 | -60.12 | -57.49 |
Additional Paid-In Capital | 2.3% | 623 | 609 | 602 | 588 | 575 | 560 | 552 | 542 | 516 | 505 | 499 | 491 | 485 | 478 | 224 | 211 | 140 | 137 | 137 | 10.00 | 1.00 |
Shares Outstanding | 0.6% | 28.00 | 27.00 | 27.00 | 27.00 | 27.00 | 27.00 | 26.00 | 26.00 | 25.00 | 25.00 | 25.00 | 25.00 | - | - | - | - | - | - | - | - | - |
Float | - | - | - | - | 311 | - | - | - | 472 | - | - | - | 1,500 | - | - | - | 519 | - | - | - | - | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | -136.8% | -6,835 | 18,587 | 5,012 | -3,786 | -25,439 | -6,000 | -5,224 | -9,001 | -21,430 | -2,781 | -6,133 | -6,438 | -3,631 | -430 | -2,955 | 13,501 | -251 | 4,493 | 752 | 482 | 1,288 |
Share Based Compensation | 7.4% | 12,675 | 11,802 | 13,043 | 12,849 | 13,525 | 9,923 | 9,196 | 8,783 | 8,419 | 6,851 | 5,210 | 4,766 | 4,913 | 2,961 | 2,118 | 1,653 | 1,577 | 713 | 229 | 139 | 168 |
Cashflow From Investing | -156.8% | -19,701 | -7,672 | -9,708 | -15,387 | 16,584 | -4,482 | -134,150 | -27,511 | -402 | -30,889 | -923 | -34,095 | -750 | -588 | -1,904 | -1,756 | -500 | -347 | -166 | -180 | -244 |
Cashflow From Financing | 422.8% | 10,644 | -3,297 | 45.00 | 226 | 728 | -750 | 388 | 661 | 1,216 | 126 | 1,894 | 1,891 | 1,510 | 227,820 | 8,150 | 69,361 | 559 | 224 | 76,421 | 936 | 10,707 |
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Income Statement [Abstract] | ||
NET REVENUES | $ 72,974 | $ 42,037 |
OPERATING EXPENSES | ||
Cost of sales (exclusive of amortization of acquired intangible assets) | 13,894 | 10,182 |
Research and development | 13,809 | 14,393 |
Selling, general and administrative | 48,495 | 46,762 |
Amortization of acquired intangible assets | 2,247 | 2,222 |
Total operating expenses, net | 78,445 | 73,559 |
Operating loss | (5,471) | (31,522) |
Interest income | 2,996 | 2,336 |
Interest expense | (14) | (4) |
Loss before income taxes | (2,489) | (29,190) |
Income tax expense | 45 | 14 |
Net loss | $ (2,534) | $ (29,204) |
Loss per share, basic (in dollars per share) | $ (0.09) | $ (1.10) |
Loss per share, diluted (in dollars per share) | $ (0.09) | $ (1.10) |
Weighted-average shares outstanding, basic (in shares) | 27,485 | 26,607 |
Weighted-average shares outstanding, diluted (in shares) | 27,485 | 26,607 |
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current Assets | ||
Cash and cash equivalents | $ 82,949 | $ 98,841 |
Marketable investment securities | 156,264 | 144,258 |
Accounts receivable, net | 42,699 | 38,302 |
Inventory | 7,645 | 7,942 |
Prepaid expenses and other current assets | 6,221 | 6,292 |
Total current assets | 295,778 | 295,635 |
Long-term accounts receivable, net | 1,056 | 1,191 |
Property and equipment, net | 32,904 | 25,433 |
Operating lease assets | 11,961 | 12,306 |
Goodwill and other intangible assets, net | 115,088 | 117,335 |
Other assets – long-term | 1,720 | 1,440 |
Total assets | 458,507 | 453,340 |
Current Liabilities | ||
Accounts payable | 9,318 | 10,268 |
Accrued compensation | 14,708 | 28,945 |
Operating lease liabilities | 1,189 | 1,137 |
Other accrued and current liabilities | 6,744 | 7,317 |
Total current liabilities | 31,959 | 47,667 |
Long-term debt | 10,000 | 0 |
Noncurrent operating lease liabilities | 13,864 | 14,173 |
Deferred tax liability | 206 | 206 |
Other liabilities | 16 | 25 |
Total liabilities | 56,045 | 62,071 |
Commitments and Contingencies (Note 11) | ||
Stockholders’ Equity | ||
Preferred stock, $0.001 par value per share; 10,000,000 shares authorized as of March 31, 2024 and December 31, 2023; no shares issued and outstanding as of March 31, 2024 and December 31, 2023 | 0 | 0 |
Common stock, $0.001 par value per share; 200,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 27,585,669 and 27,410,532 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively | 28 | 27 |
Additional paid-in capital | 623,450 | 609,477 |
Accumulated deficit | (220,905) | (218,371) |
Accumulated other comprehensive (loss) income | (111) | 136 |
Total stockholders’ equity | 402,462 | 391,269 |
Total liabilities and stockholders’ equity | $ 458,507 | $ 453,340 |